UPMC Shadyside Radiation Oncology Department
Welcome,         Profile    Billing    Logout  
 24 Trials 
26 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Heron, Dwight E
NCT02057107: SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

Completed
2
40
US
SBRT, Radiosurgery, Stereotactic radiosurgery, CyberKnife, True Beam, Trilogy, Cetuximab, Erbitux, Docetaxel, Taxotere
Heath Skinner
Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
03/19
12/19
NCT01345539: Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation

Terminated
2
24
US
Stereotactic Radiosurgery (SRS), CyberKnife, Trilogy, True Beam, Chemotherapy
Steven Burton
Oligometastatic Disease
05/22
10/22
Burton, Steve
NCT01345552: Radiosurgery for Patients Recurrent Oligometastatic Disease

Completed
2
173
US
Stereotactic Radiosurgery (SRS), CyberKnife, Trilogy, True Beam
Steven Burton
Recurrent Oligometastatic Disease
10/20
10/22
NCT01345539: Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation

Terminated
2
24
US
Stereotactic Radiosurgery (SRS), CyberKnife, Trilogy, True Beam, Chemotherapy
Steven Burton
Oligometastatic Disease
05/22
10/22
NCT02054689: Fractionated Stereotactic Radiosurgery for Large Brain Metastases

Active, not recruiting
1
20
US
Fractionated Stereotactic Radiosurgery, SRS, SBRT, CyberKnife, Trilogy, True Beam, Radiosurgery
Steven Burton
Large Brain Mets
11/17
04/24
Clump, David A
NCT02057107: SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

Completed
2
40
US
SBRT, Radiosurgery, Stereotactic radiosurgery, CyberKnife, True Beam, Trilogy, Cetuximab, Erbitux, Docetaxel, Taxotere
Heath Skinner
Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
03/19
12/19
NCT02514915: Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases

Completed
2
24
US
Stereotactic Radiosurgery
Christopher Wilke
Malignant Neoplasm Brain
07/21
07/21
MIT-001, NCT04651634: for Prevention of CCRT-Induced OM in HNSCC Patients

Recruiting
2
60
US, RoW
MIT-001 plus CCRT
MitoImmune Therapeutics
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
04/24
12/24
KEYSTROKE, NCT03546582: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Recruiting
2
102
Canada, US
Pembrolizumab, Keytruda, Stereotactic Body Radiation Therapy (SBRT), SBRT
RTOG Foundation, Inc., Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma (HNSCC)
07/27
07/29
NCT02734537: Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Recruiting
2
189
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
12/27
12/27
NCT02054689: Fractionated Stereotactic Radiosurgery for Large Brain Metastases

Active, not recruiting
1
20
US
Fractionated Stereotactic Radiosurgery, SRS, SBRT, CyberKnife, Trilogy, True Beam, Radiosurgery
Steven Burton
Large Brain Mets
11/17
04/24
NCT01360606: Stereotactic Body Radiation Therapy (SBRT) for Liver Mets

Completed
N/A
9
US
Stereotactic Body Radiation Therapy, CyberKnife, Trilogy, True Beam, Radiosurgery
Susannah Ellsworth
Liver Metastases
07/18
02/21

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
Amankulor, Nduka
ImmuneSense, NCT04485949: A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Active, not recruiting
2
93
US
IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide
Imvax
Glioblastoma
01/25
07/27
NCT02054689: Fractionated Stereotactic Radiosurgery for Large Brain Metastases

Active, not recruiting
1
20
US
Fractionated Stereotactic Radiosurgery, SRS, SBRT, CyberKnife, Trilogy, True Beam, Radiosurgery
Steven Burton
Large Brain Mets
11/17
04/24
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors

Recruiting
N/A
57
Canada, US
Focused Ultrasound (Exablate Model 4000)
InSightec
Glioblastoma, Glioma, Liquid Biopsy
12/24
03/25
Holt, Doug

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
Holeva, Karen
NCT02057107: SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

Completed
2
40
US
SBRT, Radiosurgery, Stereotactic radiosurgery, CyberKnife, True Beam, Trilogy, Cetuximab, Erbitux, Docetaxel, Taxotere
Heath Skinner
Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
03/19
12/19
NCT02128906: Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Recruiting
2
120
US
Cisplatin, Platinol, IMRT, Docetaxel, Taxotere, Cetuximab, Erbitux
Christopher Wilke
Squamous Cell Carcinoma
12/30
12/30
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
KEYSTROKE, NCT03546582: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Recruiting
2
102
Canada, US
Pembrolizumab, Keytruda, Stereotactic Body Radiation Therapy (SBRT), SBRT
RTOG Foundation, Inc., Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma (HNSCC)
07/27
07/29
NCT02054689: Fractionated Stereotactic Radiosurgery for Large Brain Metastases

Active, not recruiting
1
20
US
Fractionated Stereotactic Radiosurgery, SRS, SBRT, CyberKnife, Trilogy, True Beam, Radiosurgery
Steven Burton
Large Brain Mets
11/17
04/24
Wilke, Christopher A
NRG-BN012, NCT05438212: Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Recruiting
3
236
Canada, US
Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain
03/27
03/32
NCT02128906: Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Recruiting
2
120
US
Cisplatin, Platinol, IMRT, Docetaxel, Taxotere, Cetuximab, Erbitux
Christopher Wilke
Squamous Cell Carcinoma
12/30
12/30
NCT02514915: Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases

Completed
2
24
US
Stereotactic Radiosurgery
Christopher Wilke
Malignant Neoplasm Brain
07/21
07/21
NRG-BN010, NCT04729959: Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Active, not recruiting
2
53
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Conventional Surgery, Fractionated Stereotactic Radiation Therapy, Fractionated Stereotactic Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Tocilizumab, Actemra, IL-6 receptor monoclonal antibodies: tocilizumab, Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer, MRA, R-1569, RoActemra
National Cancer Institute (NCI), NRG Oncology
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
08/25
08/25

Download Options